Form 4: AtriCure Director Sells Shares After Option Exercise
Insider Transaction Report
AtriCure Director Sven Wehrwein exercised stock options and subsequently sold the acquired common stock on November 24 and 25, 2025.
Summary
- Director Sven Wehrwein exercised 5,033 non-qualified stock options on November 24, 2025, at an exercise price of $19.95 per share.
- On November 24, 2025, Wehrwein sold 5,033 shares of AtriCure common stock at a weighted average price of $37.32 per share.
- On November 25, 2025, Wehrwein exercised an additional 4,967 non-qualified stock options at $19.95 per share.
- Also on November 25, 2025, Wehrwein sold 4,967 shares of AtriCure common stock at $38.00 per share.
- These transactions were made pursuant to a Rule 10b5-1(c) plan.
- Following these transactions, Wehrwein's direct beneficial ownership of common stock is 34,374 shares.
- His direct beneficial ownership of non-qualified stock options decreased from 29,967 to 25,000.
Sentiment
Score: 6
Explanation: The transactions represent a director exercising pre-existing stock options and selling the resulting shares, likely for personal financial planning or diversification, as indicated by the Rule 10b5-1(c) election. This is a neutral event for the company's operational outlook, though the director realized a profit.
Positives
- Director Sven Wehrwein realized a profit by exercising stock options at $19.95 and selling the shares at an average of $37.32-$38.00.
Negatives
- Director selling shares, which could be interpreted by some investors as a lack of confidence, although these transactions were pre-planned under a Rule 10b5-1(c) plan for personal financial planning or diversification.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: May observe insider selling, which could be interpreted in various ways, but the transactions are routine for option exercises under a pre-planned trading arrangement.
Key Dates
| Date | Description |
|---|---|
| 11/11/2016 | Grant date of the non-qualified stock options. |
| 11/11/2017 | Date when 25% of the options vested and became exercisable, with the remaining 75% vesting monthly over the following three years. |
| 11/24/2025 | Transaction date for the exercise of 5,033 options and subsequent sale of 5,033 common shares. |
| 11/25/2025 | Transaction date for the exercise of 4,967 options and subsequent sale of 4,967 common shares. |
| 11/26/2025 | Signature date of the Form 4 filing. |
| 11/11/2026 | Expiration date of the non-qualified stock options. |
Recommendation
holdThe filing details routine insider transactions under a Rule 10b5-1 plan, involving the exercise of stock options and subsequent sale of shares. These pre-scheduled transactions are typically for personal financial planning and do not inherently signal a change in the company's fundamental outlook or the director's confidence. Therefore, a 'hold' recommendation is appropriate as this filing alone does not provide new information to alter an investment thesis.
Keywords
AtriCure, ATRC, Insider Trading, Stock Options, Director, Share Sale, Sven Wehrwein, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.